V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Charles River Laboratories International Executive Compensation (FY25)

CRL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
James Foster
Latest say-on-pay support
=
May 5, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Charles River Laboratories International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 21, 2026Latest filing (DEF 14A): March 31, 2026
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Charles River Laboratories International brief$1,500Get the executive brief
Velarion Member, one year
377 figures on this page: 366 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on Charles River Laboratories International

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — James Foster: $13,473,609 → $15,435,220 (14.6% higher)
CEO pay ratio: 241:1 → 251:1 (4.1% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Charles River Laboratories International's chief executive and what were they paid?
Total compensation for James Foster, Chair, President and Chief Executive Officer, came to $15,435,220 in fiscal 2025. Compared with the $13,473,609 reported for fiscal 2024, Foster's total was 14.6% higher.
What was Charles River Laboratories International's say-on-pay result?
For fiscal 2025, the say-on-pay proposal drew 93.8% support at the meeting held May 5, 2026.
Which companies are in Charles River Laboratories International's peer group?
The disclosed peer group names Abbott Laboratories, Agilent Technologies, Inc., Amgen Inc., Avantor, Inc. and Baxter International Inc., among others.
What is Charles River Laboratories International's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 251:1, against median employee compensation of $61,430.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Foster
Chairman, President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Flavia Pease
Corporate Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Joseph LaPlume
Corporate Executive Vice President Corporate Development and Strategy
◇—◇◇◇—◇◇
William Barbo
Corporate Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
David Smith
Former Corporate Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Foster
Chair, President and Chief Executive Officer
◇—◇◇◇—◇◇
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Flavia Pease
Corporate Executive Vice President and Chief Financial Officer
◇◇◇◇◇—◇◇
Joseph LaPlume
Corporate Executive Vice President, Corporate Development & Strategy
◇—◇◇◇—◇◇
William Barbo
Corporate Executive Vice President
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Foster
Chair, President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer
◇—◇◇◇—◇◇
Flavia Pease
Corporate Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Joseph LaPlume
Corporate Executive Vice President Corporate Development and Strategy
◇—◇◇◇—◇◇
Victoria Creamer
Corporate Executive Vice President, Chief People Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
James Foster
Chair, President and Chief Executive Officer
◇—◇—◇—◇◇
Birgit Girshick
Corporate Executive Vice President, Chief Operating Officer
◇—◇—◇—◇◇
Joseph LaPlume
Corporate Executive Vice President, Corporate Development & Strategy
◇—◇—◇—◇◇
Victoria Creamer
Corporate Executive Vice President and Chief People Officer
◇—◇—◇—◇◇
Michael Knell
Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer
Served on an interim basis
◇◇◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Birgit GirshickRSU◇——◇——◇
Birgit GirshickPSU◇◇◇—◇—◇
Flavia H. PeaseRSU◇——◇——◇
Flavia H. PeasePSU◇◇◇—◇—◇
James C. FosterPSU◇◇◇—◇—◇
James C. FosterRSU◇——◇——◇
Joseph LaPlumeRSU◇——◇——◇
Joseph LaPlumePSU◇◇◇—◇—◇
Michael G. KnellRSU◇——◇——◇
Michael G. KnellPSU◇◇◇—◇—◇
Michael G. KnellRSU◇——◇——◇
Victoria CreamerRSU◇——◇——◇
Victoria CreamerPSU◇◇◇—◇—◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Victoria CreamerOption◇—◇5/31/2034
Option◇—◇5/28/2031
Option◇—◇5/27/2032
Option◇—◇5/29/2030
Option◇—◇5/26/2033
RSU◇◇——
PSU◇◇——
James FosterOption◇—◇5/27/2032
Option◇—◇5/29/2030
Option◇—◇5/26/2033
RSU◇◇——
PSU◇◇——
Option◇—◇5/28/2031
Option◇—◇5/31/2034
Joseph LaPlumeOption◇—◇5/27/2032
Option◇—◇5/29/2030
Option◇—◇5/28/2031
Option◇—◇5/31/2034
PSU◇◇——
RSU◇◇——
Option◇—◇5/26/2033
Birgit GirshickOption◇—◇5/31/2034
Option◇—◇5/28/2031
Option◇—◇5/26/2033
Option◇—◇5/29/2030
Option◇—◇5/27/2032
PSU◇◇——
RSU◇◇——
Michael KnellOption◇—◇5/28/2031
RSU◇◇——
PSU◇◇——
Flavia PeaseOption◇—◇12/29/2025
Option◇—◇12/29/2025
Option◇—◇12/29/2025
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
James Foster
Chair, President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Joseph LaPlume
Corporate Executive Vice President, Corporate Development & Strategy · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Michael Knell
Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Victoria Creamer
Corporate Executive Vice President and Chief People Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Martin Mackay
Lead independent director
◇◇◇———◇
Virginia M. Wilson
◇◇◇———◇
Paul Graves
◇◇◇———◇
Craig B. Thompson
◇◇◇———◇
Nancy C. Andrews
◇◇◇———◇
Reshema Kemps-Polanco
◇◇◇———◇
George Llado, Sr
◇◇◇———◇
Steven Barg
◇◇◇———◇
Mark Enyedy
◇◇◇———◇
Abraham Ceesay
◇◇◇———◇
George E. Massaro
◇—————◇
Richard F. Wallman
◇—————◇
Robert Bertolini
◇—————◇
Deborah T. Kochevar
◇—————◇
James C. Foster served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Agilent Technologies, Inc. A
  • Amgen Inc. AMGN
  • Avantor, Inc. AVTR
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Bio-Rad Laboratories, Inc. BIO
  • Biogen Inc. BIIB
  • Boston Scientific Corporation BSX
  • Bristol-Myers Squibb Company BMY
  • Bruker Corporation BRKR
  • Catalent, Inc. CTLT
  • Eli Lilly and Company LLY
  • Fortrea Holdings, Inc. FTRE
  • Gilead Sciences, Inc. GILD
  • Hologic Inc. HOLX
  • Icon plc ICLR
  • IDEXX Laboratories Inc. IDXX
  • Illumina, Inc. ILMN
  • IQVIA Holdings Inc. IQV
  • Jazz Pharmaceuticals Public Company Limited JAZZ
  • Laboratory Corporation of America Holdings symbol not shown
  • Medpace Holdings, Inc. MEDP
  • Medtronic, Inc. MDT
  • Merck & Co., Inc. MRK
  • Mettler Toledo International Inc. MTD
  • Myriad Genetics, Inc. MYGN
  • Pfizer Inc. PFE
  • Quest Diagnostics Incorporated DGX
  • Regeneron Pharmaceuticals, Inc. REGN
  • Revvity RVTY
  • STERIS plc STE
  • Teleflex Incorporated TFX
  • Thermo Fisher Scientific Inc. TMO
  • Vertex Pharmaceuticals Incorporated VRTX
  • Waters Corporation WAT
  • West Pharmaceutical Services WST

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 5, 2026=◇◇◇
2024May 20, 2025=◇◇◇
2023May 8, 2024=◇◇◇
2022May 9, 2023=◇◇◇
2021May 10, 2022=◇◇◇
2020May 6, 2021=◇◇◇
2019May 6, 2020=◇◇◇
2018May 21, 2019=◇◇◇
2017May 8, 2018=◇◇◇
2016May 9, 2017=◇◇◇
2015May 11, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- James Foster (Chair, President and Chief Executive Officer), FY2025 total compensation $15,435,220 (base salary $1,545,636) [exec_comp, SEC accession 0001104659-26-037367, filed 2026-03-31]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Charles River Laboratories International files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Charles River Laboratories International disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Charles River Laboratories International sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Charles River Laboratories International's disclosed peer group is defensible, who names Charles River Laboratories International back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
377 figures on this page: 366 cited to the filing that reported them, 11 calculated from figures it prints.
366 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001104659-26-037367
    2025 DIRECTOR COMPENSATION · 2025 Summary Compensation Table · Compensation Discussion and Analysis · DIRECTOR COMPENSATION · and 3 more sections
  2. 0001100682-25-000023
  3. 0001104659-25-030908
  4. 0001100682-24-000020
  5. 0001104659-24-040854
    2023 Summary Compensation Table
  6. 0001100682-23-000012
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-23-038821
  8. 0001100682-22-000020
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001100682-21-000013
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001100682-20-000014
  11. 0001564590-19-020141
  12. 0001299933-18-000420
  13. 0001299933-17-000482
  14. 0001299933-16-002465
  15. 0000950103-26-007060
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Charles River Laboratories International executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CRL (accessed 2026).
Short form: data: Velarion

The paid brief for Charles River Laboratories International

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Charles River Laboratories International and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Charles River Laboratories International discloses

The companies named in CRL's own disclosed peer group.

Abbott LaboratoriesAgilent Technologies, Inc.Amgen Inc.Avantor, Inc.Baxter International Inc.Becton, Dickinson and CompanyBio-Rad Laboratories, Inc.Biogen Inc.Boston Scientific CorporationBristol-Myers Squibb CompanyBruker CorporationCatalent, Inc.Eli Lilly and CompanyFortrea Holdings, Inc.Gilead Sciences, Inc.Hologic Inc.IDEXX Laboratories Inc.Illumina, Inc.IQVIA Holdings Inc.Jazz Pharmaceuticals Public Company LimitedMedpace Holdings, Inc.Medtronic, Inc.Merck & Co., Inc.Mettler Toledo International Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy